Experimental pill nearly doubles survival time for people with advanced pancreatic cancer. ‘I actually started crying’

The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for decades.

Go to News Site